| EXAS Stock | | | USD 55.14 2.23 4.21% |
SVP
Dr. Graham Peter Lidgard, Ph.D. is Senior Vice President, Chief Scientific Officer of the Company. He joined us from Nanogen Inc., a medical diagnostics products company, where he was senior vice president of research and development from 2003 to 2009. Prior to joining Nanogen, Dr. Lidgard led the research and development organization at GenProbe Inc., a molecular diagnostics company, which developed that company Procleix blood screening products and Aptima sexually transmitted disease products, as well as the system development group at GenProbe that developed its fully automated Tigris system. Prior to joining GenProbe in 1995, Dr. Lidgard was cofounder and vice president of product development of Matritech Inc., a developer of diagnostic products for the early detection of bladder cancer. Before he cofounded Matritech, Dr. Lidgard held senior positions at Ciba Corning Diagnostics Corporationration worldwide diagnostics group. While at Ciba Corning, he was involved in the development of more than 70 510cleared products. He led the program for the development of the magnetic particle chemiluminescent technology that became the ACS180 and Centaur systems since 2009.
| Age | 75 |
| Tenure | 15 years |
| Professional Marks | Ph.D |
| Address | 5505 Endeavor Lane, Madison, WI, United States, 53719 |
| Phone | 608 284 5700 |
| Web | https://www.exactsciences.com |
Lidgard earned a bachelor degree and a doctorate in biological chemistry from the University of Manchester in England.
EXACT Sciences Management Efficiency
The company has return on total asset
(ROA) of
(0.0216) % which means that it has lost $0.0216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.0676) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.1 in 2024.
Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, EXACT Sciences'
Intangibles To Total Assets are comparatively stable compared to the past year.
Debt To Assets is likely to gain to 0.38 in 2024, whereas
Fixed Asset Turnover is likely to drop 1.58 in 2024.
EXACT Sciences currently holds 2.55
B in liabilities with Debt to Equity
(D/E) ratio of 0.77, which is about average as compared to similar companies. EXACT Sciences has a current ratio of 2.43, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about EXACT Sciences' use of debt, we should always consider it together with its cash and equity.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 6420 people. EXACT Sciences (EXAS) is traded on NASDAQ Exchange in USA. It is located in 5505 Endeavor Lane, Madison, WI, United States, 53719 and employs 6,500 people. EXACT Sciences is listed under Biotechnology category by Fama And French industry classification.
Management Performance
EXACT Sciences Leadership Team
Elected by the shareholders, the EXACT Sciences' board of directors comprises two types of representatives: EXACT Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EXACT. The board's role is to monitor EXACT Sciences' management team and ensure that shareholders' interests are well served. EXACT Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EXACT Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey CFA, Chief Officer | |
| Kevin Conroy, Chairman of The Board, CEO and Pres | |
| Ana Hooker, Chief Officer | |
| Aaron Bloomer, Executive Finance | |
| James Herriott, General VP | |
| Vic Parker, Head Sales | |
| Sarah Condella, Executive Resources | |
| Sri Kalluri, Chief Officer | |
| Tim Caprez, Chief VP | |
| Brian Baranick, Executive Oncology | |
| Nassar Nizami, Chief Officer | |
| Everett Cunningham, Chief Officer | |
| Scott Coward, Sr. VP and General Counsel | |
| Jake MBA, Executive Screening | |
| Graham Lidgard, Chief Science Officer and Sr. VP | |
| Kevin JD, Chairman CEO | |
| Jorge Garces, Chief Officer | |
| Megan Jones, Associate Relations | |
EXACT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EXACT Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to
measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to
predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.